Researchers have developed a way to predict how lung cancer cells will respond to different therapies, allowing people with ...
Dr. J. Nicholas Bodor of Fox Chase Cancer Center explains possible risk factors, symptoms to watch for, and the importance of ...
Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing ...
In a small phase II trial, radiation-free treatment with pembrolizumab (Keytruda) and platinum-based chemotherapy alone ...
Lunit (KRX:328130.KQ), a leading provider of AI for cancer diagnostics and therapeutics, today announced the presentation of ...
Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM), a leader in the development of differentiated targeted radiotherapies, today announced that the first-ever preclinical data from its ATNM-400 ...
About 5% of lung adenocarcinomas, one of the most common forms of lung cancer, are driven by a faulty fusion of two genes, EML4 and ALK. This fusion results in different variants, and until now, ...
Precision-targeted radiation is proving a match for surgery in early-stage lung cancer, offering patients similar long-term ...
Although neuroendocrine tumors of the digestive system have been studied, far less is known about those that develop in the lungs, even as their incidence appears to be on the rise.
Invasive lung squamous cell carcinoma (LUSC) accounts for approximately one-quarter of all lung cancers, but therapeutic ...
Portsmouth Regional Hospital offers cutting-edge technology used to diagnose lung. Here's what to know about it and who ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback